{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:35:00Z","timestamp":1790825700855,"version":"4.1.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"\n Importance<\/jats:title>\n Evidence suggests that elevated glutamate levels in the medial prefrontal cortex may be associated with the illness stage, but little is known about whether these effects occur in the absence of antipsychotic treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate differences in glutamate levels in treatment-naive individuals with psychosis on the schizophrenia spectrum at different stages of the illness.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional study uses proton magnetic resonance spectroscopy in the medial prefrontal cortex of individuals experiencing their first episode of nonaffective psychosis, individuals with chronic schizophrenia, and matched controls at inpatient and outpatient services of the Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City, Mexico, from November 2017 to July 2025. Data were analyzed from January 28, 2025, to August 8, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Proton magnetic resonance spectroscopy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was glutamate levels and scores measured on the Positive and Negative Syndrome Scale for Schizophrenia and the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n This cross-sectional study included a total of 181 individuals (65 with first-episode psychosis [FEP], 42 with chronic schizophrenia, and 74 age- and sex-matched healthy controls). Data from 38 participants (14 with FEP, 10 with schizophrenia, and 14 controls) were rejected from all analyses due to excessive movement or poor spectral quality, leaving 83 participants and 60 controls. The mean (SD) age was 25.9 (7.2) years for individuals with FEP, 38.0 (14.5) years for those with chronic schizophrenia, and 30.4 (11.5) years for controls. Sex distribution did not differ (34 male individuals with FEP [67.0%]; 20 male individuals with chronic schizophrenia [62.5%]; and 33 male controls [55.0%];\n P<\/jats:italic>\n \u2009=\u2009.44). Glutamate levels differed among the 3 groups (\n F<\/jats:italic>\n 2,136<\/jats:sub>\n \u2009=\u20097.5;\n P<\/jats:italic>\n \u2009=\u2009.001). Post hoc pairwise comparisons revealed higher glutamate levels in the FEP group compared with both the chronic schizophrenia group (\n P<\/jats:italic>\n \u2009=\u2009.003; Cohen\n d<\/jats:italic>\n \u2009=\u20090.69) and the control group (\n P<\/jats:italic>\n \u2009=\u2009.008; Cohen\n d<\/jats:italic>\n \u2009=\u20090.83). There were no significant differences in glutamate levels between the chronic schizophrenia group and the control group (\n P<\/jats:italic>\n \u2009&amp;gt;\u2009.99). Higher glutamate levels were associated with lower verbal (\u03c1\u2009=\u2009\u22120.29;\n P<\/jats:italic>\n \u2009=\u2009.04) and visual learning scores (\u03c1\u2009=\u2009\u22120.29;\n P<\/jats:italic>\n \u2009=\u2009.04) in the FEP group.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n These findings suggest that the differences in glutamate levels may indicate that these alterations occur primarily in the early stages of the disease. The results of this study have implications for resuming clinical trials with targeted metabotropic glutamate receptor 2\/3 agonists, taking into account both the disease phase and the glutamatergic alterations measured by magnetic resonance imaging.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.4091","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:31:10Z","timestamp":1767803470000},"page":"404","source":"Crossref","is-referenced-by-count":6,"title":["Glutamate Levels in Medial Prefrontal Cortex According to Illness Phase of Never-Medicated Individuals With Psychosis"],"prefix":"10.1001","volume":"83","author":[{"given":"Luis F.","family":"Rivera-Ch\u00e1vez","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Psychiatry, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gonz\u00e1lez-Sangabriel","sequence":"additional","affiliation":[{"name":"Neuropsychiatry Department, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"Gonz\u00e1lez-Manr\u00edquez","sequence":"additional","affiliation":[{"name":"Neuropsychiatry Department, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Moncada-Habib","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Psychiatry, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Le\u00f3n-Ortiz","sequence":"additional","affiliation":[{"name":"Neuropsychiatry Department, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Malacara","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Psychiatry, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Reyes-Madrigal","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Psychiatry, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"de la Fuente-Sandoval","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Psychiatry, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10323","key":"ybr250021r1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia.","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"ybr250021r2","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/schbul\/sbs076","article-title":"NMDA receptor and schizophrenia: a brief history.","volume":"38","author":"Coyle","year":"2012","journal-title":"Schizophr Bull"},{"issue":"12","key":"ybr250021r3","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jamapsychiatry.2013.2437","article-title":"Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia.","volume":"70","author":"Kraguljac","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"ybr250021r4","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/npp.2011.65","article-title":"Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.","volume":"36","author":"de la Fuente-Sandoval","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"ybr250021r5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamapsychiatry.2013.289","article-title":"Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.","volume":"70","author":"de la Fuente-Sandoval","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"ybr250021r6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1001\/jamapsychiatry.2021.0380","article-title":"Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: a mega-analysis of individual participant-level data.","volume":"78","author":"Merritt","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1-3","key":"ybr250021r7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2016.02.017","article-title":"Age-related changes in anterior cingulate cortex glutamate in schizophrenia: a 1H MRS study at 7 Tesla.","volume":"172","author":"Brandt","year":"2016","journal-title":"Schizophr Res"},{"issue":"7","key":"ybr250021r8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.biopsych.2018.09.009","article-title":"Glutamatergic neurometabolite levels in patients with ultra-treatment-resistant schizophrenia: a cross-sectional 3T proton magnetic resonance spectroscopy study.","volume":"85","author":"Iwata","year":"2019","journal-title":"Biol Psychiatry"},{"issue":"11","key":"ybr250021r9","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41380-018-0082-9","article-title":"Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE).","volume":"23","author":"Egerton","year":"2018","journal-title":"Mol Psychiatry"},{"key":"ybr250021r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2021.110473","article-title":"Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients.","volume":"113","author":"Reyes-Madrigal","year":"2022","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"11","key":"ybr250021r11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia.","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"4","key":"ybr250021r12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1176\/appi.ajp.2015.15050632","article-title":"Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program.","volume":"173","author":"Kane","year":"2016","journal-title":"Am J Psychiatry"},{"key":"ybr250021r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2020.108827","article-title":"Osprey: open-source processing, reconstruction & estimation of magnetic resonance spectroscopy data.","volume":"343","author":"Oeltzschner","year":"2020","journal-title":"J Neurosci Methods"},{"key":"ybr250021r14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bbi.2023.05.001","article-title":"Systemic inflammation and cortical neurochemistry in never-medicated first episode-psychosis individuals.","volume":"111","author":"Le\u00f3n-Ortiz","year":"2023","journal-title":"Brain Behav Immun"},{"issue":"1","key":"ybr250021r15","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41380-021-01297-6","article-title":"Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies.","volume":"27","author":"Nakahara","year":"2022","journal-title":"Mol Psychiatry"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2843427\/jamapsychiatry_riverachvez_2026_br_250021_1774053102.49715.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:01:22Z","timestamp":1775055682000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2843427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.4091","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}